The available literature delineating imaging features of spinal cord lesions in children with multiple sclerosis (MS) and other acquired demyelinating diseases largely predates the availability of testing for antibodies to myelin oligodendrocyte glycoprotein (MOG). This evidence concerns the gene MOG and myeloid sarcoma.